

AccuVert™ HCV Seroconversion Panel PHV926 (0610-0225)

INTENDED USE

The AccuVert™ HCV Seroconversion Panel PHV926 (0610-0225) is intended for use by diagnostic manufacturers and clinical laboratorians in evaluating their HCV test systems with well-characterized specimens. Characterized samples and comprehensive data are provided for comparative analysis. For research use only. Not for use in diagnostic procedures.

PRODUCT DESCRIPTION

This product is a 5-member HCV seroconversion panel. Panel members represent serial bleeds from a single donor during the development and progression of a HCV infection. Panel members consist of undiluted, naturally occurring plasma samples. Each sample represents a single collection event. No preservatives were added.

Material Number: 0610-0225, 1 vial per member
5 members, 1.2 mL per vial

STORAGE

Panel members should be stored frozen -70°C or colder. LGC SeraCare recommends that the panel members be divided into smaller aliquots to avoid multiple freeze-thaw cycles, if appropriate. If turbidity or particulate matter is observed, the samples should be centrifuged in accordance with each test kit manufacturer's instructions for sample preparation.

INTERPRETATION OF RESULTS

The Data Sheet for AccuVert HCV Seroconversion Panel PHV926 (0610-0225) is available at www.seracare.com. The Data Sheet lists results for panel members generated using commercially-available screening, monitoring, and confirmatory test methods. Tests were performed at LGC SeraCare or at recognized reference laboratories (RL) by individuals who routinely use these procedures. Information regarding specific test methods is available on the data sheet. Data Sheets are updated when new data are available.

LIMITATIONS

AccuVert HCV Seroconversion Panel PHV926 (0610-0225) is offered for research use only. Not for use in diagnostic procedures. Data are provided for informational purposes. LGC SeraCare Life Sciences does not claim that others can duplicate test results exactly.

PRECAUTIONS

These materials have not been treated and should be considered biohazardous. Follow Universal Precautions¹. Panel members were tested and some were found positive by tests for anti-HCV and HCV RNA. Panel members were tested and found negative for HBsAg and anti-HIV. This does not ensure the absence of these or other human pathogens.

Do not pipette by mouth. Do not smoke, eat, or drink in areas where specimens are handled.

These materials should be disposed of in a manner that will inactivate pathogenic agents.

REFERENCES

1. Siegel JD, Rhinehart E, Jackson M, Chiarello L, and the Healthcare Infection Control Practices Advisory Committee, 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings.

For assistance, contact LGC SeraCare at 508.244.6400.

The package insert for this panel can be found at www.seracare.com.

A printed copy of the package insert or data sheet may be requested by email at CDx-Info@LGCGroup.com or by phone at 508.244.6400.